UCB SA UCB.BR · Stock Open UCB SA in new tab
UCB SA Analysis (UCB.BR)
Is UCB SA a good investment? UCB SA (UCB.BR) is currently trading at 245.80 EUR. Market analysts have a consensus price target of 287.95 EUR. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 30.51. This high multiple suggests investors have priced in significant future growth expectations.
Earnings Schedule: UCB SA is expected to release its next earnings report on July 30, 2026. The market consensus estimate for Forward EPS is 13.60.
For income investors, UCB SA pays a dividend yield of 0.61%. With a payout ratio of 17%, the dividend appears sustainable.
Investor FAQ
Does UCB SA pay a dividend?
Yes, it pays an annual dividend of 1.45 EUR (0.61% yield).
What asset class is UCB SA?
UCB SA is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be July 30, 2026. The company currently has a trailing EPS of 8.02.
Company Profile
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet and Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops KYGEVVI (doxecitine/doxribtimine) for thymidine kinase 2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder, and RETT-Syndrome; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; and UCB9741 for atopic dermatitis, non cystic fibrosis bronchiectasis, and chronic obstructive pulmonary disease. Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
| Year | Total Dividends |
|---|---|
| ▸2027 |
1.48 EUR
|
| May 3, 2027 (estimated) | 1.4843 |
| ▸2026 |
1.45 EUR
|
| May 6, 2026 | 1.4500 |
| ▸2025 |
1.39 EUR
|
| April 29, 2025 | 1.3900 |
| ▸2024 |
1.36 EUR
|
| April 30, 2024 | 1.3600 |
| ▸2023 |
1.33 EUR
|
| May 3, 2023 | 1.3300 |
| ▸2022 |
1.30 EUR
|
| May 3, 2022 | 1.3000 |
| ▸2021 |
1.27 EUR
|
| May 4, 2021 | 1.2700 |
| ▸2020 |
1.24 EUR
|
| May 6, 2020 | 1.2400 |
| ▸2019 |
1.21 EUR
|
| April 30, 2019 | 1.2100 |
| ▸2018 |
1.18 EUR
|
| May 2, 2018 | 1.1800 |
| ▸2017 |
1.15 EUR
|
| May 3, 2017 | 1.1500 |
| ▸2016 |
1.10 EUR
|
| May 3, 2016 | 1.1000 |
| ▸2015 |
1.06 EUR
|
| May 6, 2015 | 1.0600 |
| ▸2014 |
1.04 EUR
|
| May 5, 2014 | 1.0400 |
| ▸2013 |
1.02 EUR
|
| May 7, 2013 | 1.0200 |
| ▸2012 |
1.00 EUR
|
| May 3, 2012 | 1.0000 |
| ▸2011 |
0.98 EUR
|
| May 5, 2011 | 0.9800 |
| ▸2010 |
0.96 EUR
|
| May 6, 2010 | 0.9600 |
| ▸2009 |
0.92 EUR
|
| May 8, 2009 | 0.9200 |
| ▸2008 |
0.92 EUR
|
| April 28, 2008 | 0.9200 |
| ▸2007 |
0.90 EUR
|
| April 30, 2007 | 0.9000 |
| ▸2006 |
0.88 EUR
|
| June 16, 2006 | 0.8800 |
| ▸2005 |
0.86 EUR
|
| June 17, 2005 | 0.8600 |
| ▸2004 |
1.32 EUR
|
| June 11, 2004 | 0.8200 |
| April 21, 2004 | 0.5000 |
| ▸2003 |
1.21 EUR
|
| June 13, 2003 | 0.8000 |
| April 15, 2003 | 0.4100 |
| ▸2002 |
1.14 EUR
|
| June 14, 2002 | 0.7600 |
| April 17, 2002 | 0.3800 |
| ▸2001 |
0.64 EUR
|
| June 14, 2001 | 0.6400 |
| ▸2000 |
0.50 EUR
|
| June 14, 2000 | 0.5000 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| UCB SA | May 06, 2026 | Paid | 1.45 EUR |
Community Discussion